Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00430547

Enrollment

Registered

2007-02-02

Start date

2003-08-31

Completion date

2006-01-31

Last updated

2007-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' Ophthalmopathy

Brief summary

The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with hyperthyroidism due to Graves' disease. The other aim of this study is to determine the incidence of the various ophthalmopathy subtypes and the utility of orbital antibodies in the diagnosis, classification and monitoring of patients with thyroid-associated ophthalmopathy.

Interventions

DRUGCarbimazole, radio-active iodine (I131)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Graves' disease diagnosed in the last 3 months, regardless of the presence of ophthalmopathy

Exclusion criteria

* Pre-existing eye disease: e.g. orbital surgery, orbital irradiation or significant loss of vision * Age \< 18 years * Inability to consent to participation in the study * Pregnancy * History of radio-active iodine therapy

Design outcomes

Primary

Measure	Time frame
Onset or progression of ophthalmopathy following radio-active iodine therapy	—

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026